The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | Long-term survival outcomes in pts with MF treated with momelotinib vs danazol in the MOMENTUM trial
Ruben Mesa, MD, Levine Cancer Institute, Atrium Health Wake Forest Baptist Comprehensive Cancer Center, Winston Salem, NC, talks on the long-term survival in patients with myelofibrosis (MF) treated with momelotinib versus danazol in the MOMENTUM trial (NCT04173494). The survival rates were similar between the two treatment arms, regardless of whether the data was adjusted for treatment crossover. However, Dr Mesa suggests that momelotinib may still offer benefits, noting that the limited sample size and study power may have influenced the results. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
The MOMENTUM study was a second line study of momelotinib versus danazol for patients with myelofibrosis, and we reported at this year’s meeting an analysis when accounting for crossover and not accounting for crossover as related to survival. Initially, we felt that there had been a bit of a difference between these arms, you know, as we were able to get kind of the totality of the data still relatively similar in terms of survival, whether we accounted for crossover or not...
The MOMENTUM study was a second line study of momelotinib versus danazol for patients with myelofibrosis, and we reported at this year’s meeting an analysis when accounting for crossover and not accounting for crossover as related to survival. Initially, we felt that there had been a bit of a difference between these arms, you know, as we were able to get kind of the totality of the data still relatively similar in terms of survival, whether we accounted for crossover or not. Still, we think that there is a very significant impact and benefit for the use of momelotinib. We think that this analysis is probably limited by the number of patients, the duration of time, kind of between the arms, you know, and the power. Functionally, having cared for many of these patients with momelotinib, you know, I have little doubt that responders really both have a benefit and probably are living much longer. But at least in terms of kind of the raw data in this analysis, we’re not able to prove that difference.
Read more...
